MiMedx Group (NASDAQ:MDXG) Lifted to Strong-Buy at StockNews.com

MiMedx Group (NASDAQ:MDXG) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.

A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. Craig Hallum dropped their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Trading Up 3.1 %

MDXG stock traded up $0.20 during midday trading on Wednesday, hitting $6.58. 768,274 shares of the company’s stock were exchanged, compared to its average volume of 756,893. The company has a market cap of $966.01 million, a PE ratio of 14.95 and a beta of 1.98. The stock’s fifty day moving average price is $6.83 and its 200-day moving average price is $7.18. MiMedx Group has a one year low of $5.57 and a one year high of $9.27. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $87.21 million for the quarter, compared to analyst estimates of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. Research analysts predict that MiMedx Group will post 0.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in shares of MiMedx Group during the 1st quarter valued at $27,000. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group during the second quarter valued at about $40,000. Quest Partners LLC bought a new position in shares of MiMedx Group during the second quarter valued at about $81,000. Loudon Investment Management LLC purchased a new position in shares of MiMedx Group during the fourth quarter valued at about $105,000. Finally, Entropy Technologies LP purchased a new position in shares of MiMedx Group during the first quarter valued at about $99,000. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.